The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1b, open-label, safety, tolerability, and efficacy study of HC-7366 in combination with belzutifan in patients with advanced or metastatic renal cell carcinoma (NCT06234605).
 
Neil Shah
Honoraria - MJH Life Sciences
Consulting or Advisory Role - Merck Sharp & Dohme Corp.
Research Funding - Aravive (Inst); Exelixis; HiberCell (Inst)
Travel, Accommodations, Expenses - Merck
 
Manojkumar Bupathi
Honoraria - Agendia; AIQ Solutions; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Bristol-Myers Squibb; EMD Serono; Exelixis; Exelixis; Exelixis; Exelixis; Janssen; Myovant Sciences; Pfizer
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Exelixis
Speakers' Bureau - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Exelixis; Janssen Oncology; Pfizer
 
Rana McKay
Consulting or Advisory Role - Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol Myers Squibb; Calithera Biosciences; Caris Life Sciences; Daiichi Sankyo; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)
 
Benjamin Garmezy
Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); crispr therapeutics (Inst); Eikon Therapuetics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Flare Therapeutics (Inst); Genentech (Inst); Harbour BioMed (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Loxo/Lilly (Inst); MiNK Therapeutics (Inst); Nuvation Bio (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Takeda (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Xencor (Inst); Zenshine (Inst); Zenshine (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Adaptimmune (Inst); Adicet Bio (Inst); AIQ Global (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Rondo Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Xencor (Inst)
 
Joel Picus
Research Funding - lava therapeutics (Inst); Merck (Inst); Novartis (Inst)
 
Moshe Ornstein
Consulting or Advisory Role - AVEO; Bristol Myers Squibb Foundation; Eisai; Exelixis; Merck; Pfizer
Speakers' Bureau - Bristol-Myers Squibb; Merck
Research Funding - Aravive (Inst); Arcus Biosciences (Inst); Astellas Medivation (Inst); AstraZeneca/MedImmune (Inst); AVEO (Inst); Bristol-Myers Squibb (Inst); HiberCell (Inst); Merck (Inst); Pfizer (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Eisai; Exelixis; Merck; Pfizer
 
Robert Figlin
Employment - 4D Medical
Leadership - 4D Medical; 4Dx
Stock and Other Ownership Interests - 4Dx
Research Funding - Merck (Inst)
 
Elaine Lam
Consulting or Advisory Role - Pathos
Research Funding - Amgen (Inst); Arrowhead Pharmaceuticals (Inst); Astellas Pharma (Inst); Biosplice (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Decibel Therapeutics (Inst); Exelixis (Inst); FORMA Therapeutics (Inst); Harpoon Therapeutics (Inst); Hibercell (Inst); Merck (Inst); OnQuality Pharmaceuticals (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); Roche/Genentech (Inst)
 
Edward Gelmann
Stock and Other Ownership Interests - Bristol-Myers Squibb (I); Johnson & Johnson (I); Lilly (I)
Research Funding - Regeneron (Inst)
Expert Testimony - Sanofi
 
Hans Hammers
Honoraria - Bristol-Myers Squibb
Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; exelixis; Lilly; Merck; Novartis; Pfizer; Surface Oncology
Research Funding - Aveo (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Hibercell (Inst); Merck (Inst); NGM Biopharmaceuticals (Inst); NiKang Therapeutics (Inst); Surface Oncology (Inst); Werewolf Therapeutics (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer
 
Brian Rank
Employment - HealthPartners, Inc
 
Song Zhao
Consulting or Advisory Role - AstraZeneca; Janssen Oncology; Novartis
Research Funding - Merck Sharp & Dohme (Inst); Pfizer (Inst)
 
Pedro Barata
Stock and Other Ownership Interests - Luminate Medical
Honoraria - UroToday
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; BMS; Caris Life Sciences; Dendreon (Inst); Eisai; EMD Serono; Exelixis; Ipson; Merck; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Bayer (Inst); Caris Life Sciences (Inst); Merck; Pfizer/Astellas (Inst)
Research Funding - AVEO (Inst); Blue Earth Diagnostics (Inst); Exelixis; Merck (Inst); Pfizer (Inst)
 
Mohamad Salkeni
Employment - Next Oncology; Virginia Cancer Specialists
Stock and Other Ownership Interests - Next Oncology
Honoraria - Healthcasts
Consulting or Advisory Role - Daiichi Sankyo
Research Funding - 1ST Biotherapeutics (Inst); Acrivon Therapeutics (Inst); Agenus (Inst); Aprea Therapeutics (Inst); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bolt Biotherapeutics (Inst); Chugai Pharma (Inst); Compugen (Inst); CrystalGenomics (Inst); Daiichi Sankyo US (Inst); Epizyme (Inst); Exelixis (Inst); HiberCell (Inst); IDEAYA Biosciences (Inst); Inmune Bio (Inst); Ionova (Inst); Kronos Bio (Inst); MBrace Therapeutics (Inst); Merck (Inst); Nested Therapeutics (Inst); OncoResponse (Inst); Oncternal Therapeutics (Inst); Pasithea Therapeutics (Inst); Pathos (Inst); Pheon Therapeutics (Inst); Prelude Therapeutics (Inst); Schrodinger (Inst); Stemline Therapeutics (Inst); Takeda (Inst); Tarus Therapeutics (Inst)
 
Yusra Shao
Honoraria - AVEO; Castle Biosciences; Immunocore
Consulting or Advisory Role - AVEO; Castle Biosciences; Immunocore
Travel, Accommodations, Expenses - Castle Biosciences
 
Scott Tykodi
Honoraria - CancerNetwork; FirstWord; OncLive/MJH Life Sciences; Targeted Oncology; Topline Bio
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; Exelixis
Research Funding - AVEO (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); HiberCell (Inst); Iovance Biotherapeutics (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Xencor (Inst)
Travel, Accommodations, Expenses - DAVA Oncology
 
Thomas Hutson
Employment - Texas Tech University Health Science Center
Honoraria - Eisai; Exelixis; Pfizer
Consulting or Advisory Role - Eisai; Exelixis; Johnson & Johnson; Pfizer
Speakers' Bureau - Eisai; Exelixis; Pfizer
Research Funding - Eisai (Inst); Exelixis (Inst); Johnson & Johnson (Inst); Pfizer (Inst)
 
Michael Chisamore
Employment - Merck
Stock and Other Ownership Interests - Merck
 
Jose Iglesias
Consulting or Advisory Role - ALLARITY THERAPEUTICS; Amplia Therapeutics; Carina Biotech; DUO ONCOLOGY; Epsilogen; HIberCell; Panavance Therapeutics
 
Robert Motzer
Consulting or Advisory Role - Aveo; EMD Serono; Exelixis; Incyte; Merck; Takeda
Research Funding - Aveo (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb